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none of the drugs supporting psychotherapy in treatment of alcoholism is reim-
bursed, and new, in which naltrexone is reimbursed within the catalogue of guar-
anteed health services in the treatment of alcohol-dependent patients. The anal-
ysis presents the costs incurred by public payer and by patient associated onlywith
drugs that support psychotherapy in the considered target population. The costs
were not discounted. Consumption of resources was estimated on the basis of
epidemiological data and recommended duration of pharmacotherapies. The ef-
fect of changes of key parameters and assumptions of primary analysis on the
results obtained from the perspective of the public payer was examined in the
one-way sensitivity analysis. RESULTS: If the reimbursement of naltrexone is in-
troduced, the annual expenses from the budget of National Health Fund would
increase by PLN11.7million in the first year, and PLN11.8million in the second year
of reimbursement. On the other hand, from the patient perspective reimbursement
of naltrexonewill bring significant cost savings whichwill annually amount to PLN
28.8 million in the first and second year of the refund. CONCLUSIONS: Reimburse-
ment of naltrexone in the treatment of alcohol-dependent patients in Poland will
bring additional costs incurred by public payer (National Health Fund) andpatient’s
significant cost savings.
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OBJECTIVES:To comparepatterns of psychotropicmedicationuse and the associated
costs among children with autism spectrum disorder (ASD) between public and pri-
vate insurance to bridge a knowledge gap in the literature.METHODS: Retrospective
analyses were done using year 2003 claims data from Medicaid and the MarketScan
databases, a national sample of privately insured individuals. Two-sample z-tests
were used to compare the proportions. T-testswere used to compare themeans given
the large sample size. RESULTS:A total of 18,166 childrenwith ASDwere identified in
Medicaid and 2,716 in MarketScan. Psychotropic medication was used by 86% of ASD
children in Medicaid and 78% in MarketScan. The psychotropic medication costs per
ASD patient were nearly twice higher in Medicaid ($1464 vs. $796, p0.0001). The
twelve most costly psychotropic drugs accounted for 82% of all psychotropic drug
costs, with Medicaid spending more on all these drugs. Risperidone, the most costly
drug in both systems, cost $391 per ASD patient in Medicaid and $218 in MarketScan.
ThehigherMedicaid costwas due tomore users (27%vs. 18%) andhigher average cost
per risperidone user ($1612 vs. $1242). Though the unit cost was similar, the average
lengthof therapywas longer inMedicaid (241vs. 210days). Similarpatternsexisted for
other drugs such as olanzapine, the second most costly psychotropic medication in
Medicaid. Medicaid hadmore olanzapine users (7.4% vs. 4.5%), higher costs per olan-
zapineuser ($2276vs. $1302)due tomoredays supplied (211vs. 156days),with theunit
cost being similar. CONCLUSIONS: Children with ASD in Medicaid had much higher
psychotropicdrug costs than those in commercial insurance. Similar drugswereused,
but the same drugs cost much more in Medicaid, due to a higher percentage of chil-
dren on the medication and a greater duration of use.
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BACKGROUND: Differences in daily utilization of antidepressant therapies may
have clinical and economic implications, particularly pharmacy expenditures for
health plans. OBJECTIVES: To examine antidepressant daily average consumption
(DACON) and drug cost per day for patients with major depressive disorder (MDD)
newly initiating serotonin- norepinephrine reuptake inhibitors (SNRIs) or
escitalopram. METHODS: A retrospective cohort analysis was conducted in com-
mercially insured patients from July 1, 2008 through June 30, 2009. Patients diag-
nosed with MDD (ICD-9: 296.2x, 296.3x, or 311) and newly treated with generic
desvenlafaxine, venlafaxine XR, duloxetine, or escitalopram were included. For
each index medication, DACON was computed for each pill strength by dividing
total units dispensed by total days’ supply while the patient persisted on index
therapy, then averaging across pill strengths,weighted by days’ supply. Persistence
was defined as length of therapy without exceeding a 30-day gap in drug coverage,
and drug cost per daywas estimated based on standardwholesale acquisition cost.
RESULTS: The study population included 1,097 desvenlafaxine, 1,924 venlafaxine
XR, 3,216 duloxetine, and 4,730 escitalopram initiators. Average DACON during the
study period was significantly lower (P0.001) for desvenlafaxine (1.04) vs venla-
faxine XR (1.43), duloxetine (1.28), or escitalopram (1.07). Average cost per DACON
during the study periodwas significantly lower (P0.001) for desvenlafaxine ($3.89)
vs venlafaxine XR ($6.13) and duloxetine ($5.45), but higher than escitalopram
($3.21). Average persistence (days) was significantly greater for desvenlafaxine
(140.6) vs venlafaxine XR (127.3; P0.001), duloxetine (133.4; P0.007), and escita-
lopram (121.8; P0.001). CONCLUSIONS: Patients with MDD treated with desven-
lafaxine had significantly lower DACON and greater persistence on index antide-
pressant therapy than patients treated with venlafaxine XR, duloxetine, or
escitalopram, and the lowest DACON cost among the SNRIs. Health care decision
makersmaywish to consider utilization patterns and their economic impact when
determining health care policy and treatment decisions.
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OBJECTIVES: To compare patterns of healthcare utilization and cost in the
6-month periods immediately before and after the initiation of benzodiazepine
therapy among patients with generalized anxiety disorder (GAD) deemed long-
termusers of such therapy.METHODS:Using a largeUShealth insurance database,
we identified all persons with evidence of GAD (ICD-9-CM diagnosis code 300.02)
between 1/1/2003 and 12/31/2007 who began treatment with a benzodiazepine
anxiolytic. The date of the first benzodiazepine claim was designated the “index
date”, andwe limited attention to patientswith evidence of use of benzodiazepines
for 90 days. Patients with 6 months of complete data preceding and following
their index date were excluded from the study sample (“pre-index” and “post-
index”, respectively). We then compared healthcare utilization and costs between
the 6-month pre-index and post-index periods. All healthcare utilization—and cor-
responding costs—was characterized as possibly attributable to long-term use of
benzodiazepines (such as “accident-related” [e.g., fractures] or “other possibly re-
lated” [e.g., mental confusion/disorientation, cognitive impairment, dizziness]) or
not, based on relevant ICD-9-CM diagnosis codes. RESULTS:We identified a total of
866 patients who initiated benzodiazepine therapy for GAD and who met all other
entry criteria; 75% began monotherapy with benzodiazepines, and 25% received
such therapy on an add-on basis. Mean total healthcare costs over the 6-month
post-index period increased by $2334 relative to pre-index (from $4637 [SD$9840]
to $6971 [$17,002]; p0.01); the corresponding increase for care possibly attributed
to long-term use of benzodiazepines (i.e., accident-related, other possibly related)
was $1099 ($1757 [$7656] vs. $2856 [$14,836]; p0.04). CONCLUSIONS: Healthcare
costs increase in patients with GAD who receive90 days of benzodiazepine ther-
apy; a substantial proportion of this increase is attributable to care associated with
accidents and other known sequelae of long-term benzodiazepine use.
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OBJECTIVES: To compare the differences in healthcare costs and utilizations be-
tween opioid-dependent patients who were treated with and without medication.
METHODS:We conducted a retrospective database analysis using commercial en-
rollees from a large U.S. health plan database from 2005 to 2009. Continuously
eligible patients with at least one claim of opioid dependence during the identifi-
cation period and an opioid use disorder diagnosis during the baseline period were
included. Propensity score matching was applied to compare the risk-adjusted
outcomes between the Any Medication Group and the No Medication Group. Base-
line differences in age, gender, region, comorbid scores, socio-economic status,
baseline healthcare utilization and costs were controlled. RESULTS: Descriptive
analysis showed that patients in the AnyMedication Group (n10,523) were sicker,
had more distinct psychiatric diagnoses and medication, and were more likely to
have an Elixhauser index score ofmore than 3when compared to patients from the
No Medication Group (n8,630). After risk adjustments, 6,658 patients from each
group were matched. Patients in the No Medication Group stayed significantly
longer in detoxification facilities, and had a higher number of detoxification and/or
rehabilitation admissionwhich translated to a higher cost burden. Also, patients in
the No Medication Group had more opioid-related and substance abuse psychos-
ocial provider services and higher total healthcare costs during a 6-month post-
index period compared to patients in the Any Medication Group. CONCLUSIONS:
After controlling for confounders such as demographic factors, comorbid condi-
tions and baseline healthcare utilization, we showed that medication treatment
affects follow-up healthcare resource utilization and costs. Patients treated with-
outmedication incurredhigher healthcare costs andutilizations thanpatientswho
were treated with medication.
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OBJECTIVES: To compare the differences in healthcare costs and utilizations be-
tween alcohol-dependent patients treated with pharmacological substances and
those treated with non-pharmacological substance medication. METHODS: We
conducted a retrospective database analysis using commercial enrollees from a
large U.S. health plan database from 2005 to 2009. Continuously eligible patients
with at least one claim of alcohol dependence during the identification period and
an alcohol use disorder diagnosis during the baseline period were included. Pro-
pensity score matching was applied to compare the risk-adjusted outcomes be-
tween the No-Pharmacological Substance Group and the Any Pharmacological
Substance Group. Baseline differences in age, gender, region, comorbid scores,
socio-economic status, and baseline healthcare utilization and costs were
controlled. RESULTS: Descriptive analysis shows that patients in the Any Pharma-
cological Substance Group (n15,502) were older, more likely to be female, had
more distinct psychiatric diagnoses and medication, and were more likely to have
an Elixhauser index score of more than 3 when compared to patients from the
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